# Bevacizumab/Doxorubicin/Radiation for Sarcoma

> **NCT01746238** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 14 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Doxorubicin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT01746238
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-03
- **Primary completion:** 2016-05
- **Final completion:** 2026-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746238, "Bevacizumab/Doxorubicin/Radiation for Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01746238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*